Doç. Dr. Özlem Nuray Sever
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Carcinoma, Renal Cell 11 publicationsSource: OpenAlex / PubMed MeSHView publications
- Kidney Neoplasms 11 publications
- Breast Neoplasms 5 publications
- Lung Neoplasms 4 publications
- Bone Neoplasms 2 publications
- Colonic Neoplasms 2 publications
- Carcinoma, Non-Small-Cell Lung 2 publications
- Colorectal Neoplasms 2 publications
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyMedical Oncologysaglik.gov.trFrom source
- InstitutionSancaktepe Şehit Prof. Dr. İlhan Varank Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
- Area of workCarcinoma, Renal CellExtracted from 11 publications · Model version —From source
- Publications81 publicationsOpenAlex, ORCIDFrom source
- ORCID0000-0003-3462-9360ORCIDFrom source
- Last synchronised5 November 2026 08:56https://sancaktepeah.saglik.gov.tr/TR-1488548/doktorlarimiz.html#ozlem-nuray-seversaglik.gov.tr
Scientific work
Publications on Carcinoma, Renal Cell
-
Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study
Clinical Medicine Insights Oncology, 2026
DOI 10.1177/11795549261445290 PMID 42131419 Open-access full textSource: OpenAlex
-
Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors
JCO Global Oncology, 2026
DOI 10.1200/go-25-00234 PMID 41855443 Open-access full textSource: OpenAlex
-
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study
Cancers, 2026
DOI 10.3390/cancers18132127 PMID 42449669 Open-access full textSource: OpenAlex
-
Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
BMC Cancer, 2026
DOI 10.1186/s12885-026-16664-1 Open-access full textSource: OpenAlex
-
Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
Scientific Reports, 2026
DOI 10.1038/s41598-026-35435-3 PMID 41548007 1 citation (OpenAlex) Open-access full textSource: OpenAlex
-
Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study
Cancer Control, 2026
DOI 10.1177/10732748261432273 PMID 41779425 Open-access full textSource: ORCID
-
Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer
Current Oncology, 2026
DOI 10.3390/curroncol33020078 PMID 41744842 1 citation (Europe PMC) Open-access full textSource: ORCID
-
Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage
Journal of Clinical Medicine, 2025
DOI 10.3390/jcm14197103 PMID 41096183 4 citations (Europe PMC) Open-access full textSource: OpenAlex
-
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
BMC Cancer, 2025
DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 citations (Europe PMC) Open-access full textSource: OpenAlex
-
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium
癌症：英文版, 2025
DOI 10.1002/cac2.70003 PMID 39927571 1 citation (Europe PMC) Open-access full textSource: OpenAlex